in achieved XX% moment highest And strong second Thank exciting an quarter incredibly in Insmed. are XXXX, quarter. commercial in everyone. compared at of to we What an Brian. good From sales the up morning, quarterly a you, our first we history, perspective, the already
expectations, what of commercial really humming. midpoint outperformance, the the making scenario Insmed result the is was revenue guidance. range now year, we current this the best-case of a our guidance at As are raising of for our engine Clearly, under our previous
teams the day future our as and profitable colleagues the extraordinary approvals, be brensocatib clinical which are world in thank which result. organization. successful assets, and the a customer-facing to with their led same And If of and these sustainable company's increases my efforts, confidence this part one organization launch will pipeline to commercial I throughout we our want other the us trials to for
exciting been in is what this store. even we performance as more quarter's impressive As has have
now to finally the at the for time brensocatib arriving data of portfolio, entire we year. we anticipating release the meaningful expect have across produce development are our the been quarter when next second in ASPEN and We data culminating of for years in research
ASPEN culmination because catalyst mentioned it period as of undoubtedly is milestone means history this a the of updates. company. huge end meaningful the I our the But in of of by mark will this no R&D ASPEN
keep be give will you please taste in of list mean, me Let that exhausted. what not a this I and mind
manufacturing gene AlgaeneX program, In our the parallel, data In a production Algae, filings we therapy XXXX, we anticipate of including programs, patient additional of will validating have using to believe one we including in gene DMD first steady and potentially for disease. from our an capsids Stargardt IND updates stream therapy complete other accomplished two platform.
IND our into up moving first manufacturing scale XXXX, successful Then platform the expect de-immunized of our submission to commercial using Algae. from by proteins potentially design we and full
recent will We IND is more about tell moment. a that also for in which you acquisition to an Ataxia-telangiectasia, related a to I file expect
in first be are they Insmed, line several from addition which studies to other three successful. would results All catalysts our for if potential derisk of significantly these data opportunities commercial could top large pillars, from
with those of pulmonary ongoing of in study TPIP One our patients hypertension. is arterial
using Another polyps. the be enrollment. numbers without and year brensocatib options pace this to an polyps like of few is very high rhinosinusitis patients. unmet these bronchiectasis, respective timing top area of treatment our or ultimately determined without studies no nasal nasal large patients for affected The end each of plan with line for readouts of a study, need of chronic by which is the before Much with initiate we CRS in indication second from will
it with is, It have patients newly the of ARIKAYCE MAC will infection month as to say the diagnosed line is we beginning wait lung that deliver Insmed, top and started for of next All is from the of with start can't or results it. not in antibiotics. study who as recurrent only exciting all ARISE that release year, to next our
I in set? spoke as endpoint the quarter. readout of I'm which used often the set good goal at look patient-reported to this reminder, a what about the data last will data be trial. asked, this ENCORE registration-enabling this as length in data a would tool, like is validate But primary outcome
the would From include three perspective, elements. ideal outcome key my
patient to this First, profile for course, want well-tolerated the population. of and safe a we that will, use see demonstrates in medicine
we works used PRO a for the as can us Second, ideal to primary ENCORE. in their therefore upon that show clearly when would relied the PRO that and measure need can modification. amount feeling give meaningful of This that be confidence significant predict be have a are a patients in symptoms improvement data without the endpoint would
ARIKAYCE trend the which third, for the significant compared the in conversion ENCORE see toward statistically arm. us a culture conversion and ideally levels, would the to and And at superiority PRO path outcome be would control clear a culture a we achieve at PRO arm trends study. Both give to least want to
To improvements the conversion, in can in placebo-adjusted we the to trial, to if range of in arm we and/or XX% believe be encouraging. would meaningful ARIKAYCE and time more see conversion improvement a on rates in be culture very the if the ARISE that we achieve specific XX% conversion
indication, the current financial Xx move I significant growth we result, to Xx ARISE our add an adding by than source consider one of revenue boxes, own, sustainability. is then strengthen the would financial which If all extremely which to as disease position of greatly its ARIKAYCE would a refractory we significantly opportunity on broader it the in confidence checks in lung positive believe, potentially even towards which indication in our would those MAC larger
As ARISE to the discuss top a call line once will we host shared. are a reminder, data results conference the
give remained and trial continue we an me program, to ARIKAYCE expect patients end of we to update the by let on enroll year. Enrollment the well. development as you While strong, are has XXX this ENCORE the in discussing
Treprostinil to this are TPIP, with time associated PAH. Hypertension have in share, from the Lung we Arterial Following Powder, studying Pulmonary currently data which we another Disease, data, our Palmitil program, Interstitial ARISE Pulmonary PH-ILD, Hypertension, will Inhalation set or and quickly
XXXX. blinded follow X underappreciated expect TPIP the dose data to and of to my Phase continue XXXX, is first expected readout in to top in We probably our half half from Insmed's share second Phase line opinion, pipeline studies titration X with PAH the asset. the most of In PH-ILD PH-ILD
a well profile. its PH-ILD, about and with Given patients used for that we well-known is treprostinil PAH medicine and know a quite already lot
of know doses a dose-dependent First, improvement administering treprostinil results higher in patient in that response. we
more Second, times throughout that know attempt short patients night day we doses and to day drug four the to requires a troughs relatively these half-life, the treprostinil sleep. maximize to of maintain has drug's dose it an and This exposure in of patients of per unable delivery. results full the which spikes a inhale during in or effect
to there while TPIP we for a dosing which steadily maintaining inside schedule large and they TPIP is finally, could and treprostinil prodrug, converted market know in the their sleep. already And allow growing day to cut to a even rapidly day once down gets lungs. and the effect patients once while slowly throughout that indications. is a If treprostinil steady treatment successful, these a
has significantly treprostinil result TPIP quantities Beyond the potential We the believe deliver of than larger believe the dose inhaled highest we that to at daily enhanced currently treprostinil efficacy. that, that in these could safely available higher even products. approved doses
very titration meaningful. data would blinded is that dose you is from say with normally, Now And might I ongoing still study to that likely agree be you. a not
TPIP be could how dosed. is know exception However, we and it that about given an currently already what treprostinil
of the per XXX day, each delivered micrograms, FDA-approved dose maintenance totaling to DPI the Tyvaso is XX X highest day. For micrograms lung being context, times
XXX titrate micrograms carbon in XX% studies nearly of delivered are data That of per when XX molecule. the daily Phase the exclude once will is whether to can weight higher our Our This us a that of designed being done chain be day. blinded X treprostinil to show amount blinded you of manner. early mechanism successfully it TPIP for these benefits patients to would potential is that greater If of provide I sign and encouraging we very show a a safe to up data for the per tolerable day, the that argue, history this the XXX micrograms patients. titrate can up given
see this at about the more what are look you patient the in point. very with We seen signals the encouraging. is with interest To watching efficacy about great such we efficacy, studies, small also the resistance. reduction of blinded blinded the we future, Granted, and key dose so emphasize far signals efficacy from in we've pulmonary data. as forward that data numbers are But point apart some sharing to still from titration is those vascular the
or The human This showed lead the enhanced intrathecal dosing, early-stage our In will next XXXX, one our releasing at half first come readout we that May time. on have be biopsy clinical the believe we you work data from program. Day. least since preclinical of from and engine data R&D patient fourth at patients Muscular for which in to expect look that pillar, our at efficacy we Dystrophy to anticipate unveiled using therapy and we our exciting first for could we data gene our which will safety these continued recent Duchenne produce research based
for could for gene serve also additional an readout that platform our which point add more successful, Importantly, validation therapy INDs would confidence earlier. this to data as DMD, mentioned broadly, of I if the in our important
in with This ever single I about at its company, Now is success. trial clinical running I'm and now I right brensocatib important the Insmed, most for want as clearly of the likelihood as at bronchiectasis. confident remain to conclude development non-CF program. the enthusiastic our in most trial ASPEN the
it. tell in about will most line be that we can't company's can next the of year event excited The ASPEN history, top the wait program. the aren't readout only I in ones second for this impactful the we and you quarter
Bronchiectasis will of time the data most weeks for that We Conference change everything said two history World to at one agree set this the year and in believe next community. they Just KOL that bronchiectasis patient will the New York us ago City, exciting in XXX%. be
we Before Adrestia it within completed remarks Cambridge of In our of in early-stage privately Sara to research, some June, United we touch not on at important yet called on development Therapeutics. the over a want our event. another the financials, out R&D held company to acquisition for quarter's turn briefly I Kingdom the could discuss which I
open such focus with diseases. targets diseases the patient rescue, of or as ASOs of targets has modality up the untreatable been synthetic best even CRISPR the a screens, in human could identifying select then of addressing therapies. application past the gene these area possibility population, the novel Through genetics, in with oligonucleotides, Adrestia intended the advanced small is Adrestia's have be combined for which been it across on They siRNA range therapy. and broad molecules, gene of which based
often The devastating first a it. condition second Ataxia of decade indication currently has be third is will treat nothing the or to fatal by life approved that and telangiectasia,
count, in terms Although strides moving Adrestia forward terms in have of is groups work patient establishing a lean tremendous of advocacy their community. of they and relatively that on company with made behalf head themselves
in have to space the expect you We in also filed some the the anywhere synthetic thousands cancer from which a But blockbuster technologies work Professor, University scientists sense find today whose will lethal to DNA impressive world. now Steve what just most the medicine, brought brightest addition colleagues led including alone. that, and the indication around acquisition in we world's XXXX. of This patients would being of Lynparza, Jackson Sir first to IND the in for into world, of an the and repair Insmed make know we for is benefiting past damage welcomed as medication, this Cambridge,
undoubtedly just of share we Adrestia in more have with culture kindred people Adrestia pleased combining I'm good be shown spirits What asked culture to companies for There Insmed. not couldn't a found the will the to group of say history but when works have is As a about much that is well with as future. Adrestia fit. great scientists we the has are, better at only aligned. that
cutting-edge and by are from researchers coming team we New Adrestia excited now, other For on Hampshire, chance done for in work meet the to our between look early Jersey forward San updating people to We being the you incredible behind you of giving interactions the and sites this team's work developments at some the plans and and New a it. and Diego. collaboration the
about changes pillar our Importantly, this spending. keep less acquisition previous XX% the our of commitment investment activities to nothing fourth our to overall than in
through first path multiple to estimates flowing pillars cover our two from the on to the are new around putting to the of future, bring for for the even the our programs cash of Furthermore, as the the we early-stage world. development as revenue we Insmed contemplating, market we patients medicines anticipated production financial will look more than sustainability benefit currently a clinical needs
turn financials. to second I'll Sara the call to now quarter over through our walk
